Roger Keresztes - Concepedia

Author

Roger Keresztes

Also Known As

Keresztes,Roger, R. Keresztes, R. S. Keresztes, R.S Keresztes, R.S. Keresztes, Roger Keresztes, Roger S Keresztes, Roger S. Keresztes

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Cornell University National Cancer Institute Stony Brook University Memorial Sloan Kettering Cancer Center Columbia University

About

Roger Keresztes is an author at Cornell University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	438
2	Engineering	1	1	100
3	Health Sciences	1	1	100
4	Biochemistry	1	1	59
5	Cell Biology	1	1	37

Roger Keresztes

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer Robert S. Sandler, Susan Halabi, John A. Baron, New England Journal of Medicine	2003	1.1K
Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer Nasser K. Altorki, Roger Keresztes, Jeffrey L. Port, Journal of Clinical Oncology	2003	272
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342 Eric P. Winer, Donald A. Berry, Susan Woolf, Journal of Clinical Oncology	2004	270
Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer Ali O. Güre, Elisabeth Stockert, Matthew J. Scanlan, Proceedings of the National Academy of Sciences	2000	235
Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer Jeffrey L. Port, Michael S. Kent, Robert J. Korst, The Annals of Thoracic Surgery Positron Emission TomographyPreoperative ChemotherapyPredicts ResponseEngineeringOncologic Imaging	2004	100
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study Luis Paz‐Ares, Óscar Juan, Giannis Mountzios, Journal of Clinical Oncology	2024	91
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer Missak Haigentz, Mimi Kim, Catherine Sarta, Oral Oncology Neck CancerOncologyPhase Ii TrialMedicineRecurrent/metastatic Head	2012	90
Survival Outcomes Among Lung Cancer Patients Treated Using a Multidisciplinary Team Approach Thomas V. Bilfinger, Denise Albano, Muhammed Perwaiz, Clinical Lung Cancer	2018	82
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin, Annals of Oncology Nivolumab Versus DocetaxelMedicinePharmacologyAnti-cancer AgentPhase Iii Study	2023	78
Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non–Small-Cell Lung Cancer Rogério Lilenbaum, Mark A. Socinski, Nasser K. Altorki, Journal of Clinical Oncology	2006	61

Page 1